[Three-dimensional conformal radiation therapy for prostate cancer in Hamamatsu Medical Center].
We retrospectively evaluated acute and late radiation morbidity and short-term PSA relapse-free survival of 53 patients with localized prostate cancer who received three dimensional radiation therapy (3D-CRT) that targeted prostate and seminal vesicles in Hamamatsu Medical Center from 1999.10 to 2005.4. The total dose was increased from 70 to 74 Gy in increments of 2.0 Gy. We divided these patients into two groups who received 70-72 Gy or 74 Gy. Then we analyzed whether there were differences between those two groups in acute radiation morbidity. We also analyzed late radiation morbidity in the 70(-)-72 Gy group. Acute radiation morbidity and late morbidity were described according to the RTOG acute radiation morbidity scoring criteria 1995 and RTOG/EORTC late radiation morbidity scoring scheme 1995, respectively. No acute grade 3 or 4 toxicity and no late grade 4 toxicity was observed. Late grade 3 rectal bleeding was observed in only one patient who received 70 Gy. Acute toxicity was well tolerated and did not correlate with total dose.
Kanda
Toshihiro
T
Department of Urology, Hamamatsu Medical Center.
Nakagomi
Kazuaki
K
Goto
Syuichi
S
Iijima
Mituharu
M
D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D007410:Intestinal Diseases / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000209:etiology*; D011879:Radiotherapy Dosage; D020266:Radiotherapy, Conformal / Q000009:adverse effects* / Q000379:methods*; D012189:Retrospective Studies; D012669:Seminal Vesicles / Q000528:radiation effects
D017430:Prostate-Specific Antigen